Guggenheim Upgrades Guardant Health (NASDAQ:GH) to Buy

Guggenheim upgraded shares of Guardant Health (NASDAQ:GH) from a neutral rating to a buy rating in a research report sent to investors on Friday, Marketbeat reports. They currently have $36.00 price target on the stock.

A number of other research analysts have also commented on GH. Jefferies Financial Group began coverage on Guardant Health in a research report on Monday, June 3rd. They set a buy rating and a $32.00 price target for the company. The Goldman Sachs Group lowered their price target on Guardant Health from $32.00 to $28.00 and set a buy rating for the company in a research report on Monday, April 15th. Craig Hallum began coverage on Guardant Health in a research report on Wednesday, April 24th. They set a buy rating and a $28.00 price target for the company. Canaccord Genuity Group upped their price target on Guardant Health from $30.00 to $38.00 and gave the company a buy rating in a research report on Tuesday, June 4th. Finally, Stephens reiterated an overweight rating and set a $44.00 target price on shares of Guardant Health in a report on Friday, May 24th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of Moderate Buy and an average price target of $36.83.

Guardant Health Trading Down 0.6 %

NASDAQ GH opened at $28.88 on Friday. Guardant Health has a 1-year low of $15.81 and a 1-year high of $41.06. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. The stock has a 50-day moving average of $24.98 and a 200-day moving average of $22.94. The firm has a market cap of $3.53 billion, a PE ratio of -7.37 and a beta of 1.15.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.94). The company had revenue of $168.49 million during the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. As a group, sell-side analysts forecast that Guardant Health will post -3.31 EPS for the current year.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Guardant Health by 5.8% during the 3rd quarter. Rhumbline Advisers now owns 159,660 shares of the company’s stock valued at $4,732,000 after purchasing an additional 8,688 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Guardant Health by 201.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 170,734 shares of the company’s stock valued at $5,061,000 after purchasing an additional 114,128 shares during the last quarter. Northern Trust Corp boosted its stake in Guardant Health by 2.1% during the 3rd quarter. Northern Trust Corp now owns 1,103,688 shares of the company’s stock valued at $32,713,000 after purchasing an additional 22,548 shares during the last quarter. Fred Alger Management LLC purchased a new stake in Guardant Health during the 3rd quarter valued at $1,536,000. Finally, Gotham Asset Management LLC boosted its stake in Guardant Health by 4.8% during the 3rd quarter. Gotham Asset Management LLC now owns 29,158 shares of the company’s stock valued at $864,000 after purchasing an additional 1,335 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.